Actively Recruiting
Phase 12 Study Evaluating REGN22530 for Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Led by Regeneron Pharmaceuticals · Updated on 2026-09-28
271
Participants Needed
1
Research Sites
11 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an experimental drug called REGN22530 to treat adults with primary open angle glaucoma or ocular hypertension. This drug is designed to bind to a protein in the eye that causes fluid buildup and increased intraocular pressure IOP, which can damage vision. The study aims to assess the drugs side effects, how it behaves in the body and eye fluid, immune reactions, and its effect on eye pressure to understand why it may work better in some people than others. Participants will receive REGN22530 according to the study protocol. The trial includes multiple phases and parts where the drug is administered and monitored over time to assess safety and effectiveness. The study uses a randomized design with masking to reduce bias and includes up to 24 weeks of monitoring for drug levels, immune responses, and adverse events. During the study, participants will undergo eye exams and imaging to measure visual acuity and intraocular pressure. Blood samples will be collected to measure drug concentration and immune reactions. Researchers will monitor side effects up to 24 weeks, with primary outcomes focusing on treatment-emergent adverse events and changes in eye pressure by day 85. Total participation may last several months, with ongoing safety and effectiveness assessments.
CONDITIONS
Brief Title
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here